Spitalul Clinic De Urgenta Prof Dr Agrippa Ionescu

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Heart failure4 trials
• Lung cancer3 trials
• HIV2 trials
• Atrial fibrillation1 trial
• Chronic kidney disease1 trial
• Coronary artery disease1 trial
• Hepatitis C1 trial
• Hypertrophic cardiomyopathy1 trial
• Ovarian cancer1 trial
• Prostate cancer1 trial
• Stroke1 trial

Phase

• Phase 312 trials
• Phase 2/32 trials

Status

• Recruiting7 trials
• Active, not recruiting3 trials
• Completed2 trials
• Not yet recruiting2 trials

Lead sponsor

• Boehringer Ingelheim3 trials
• Gilead Sciences Inc.2 trials
• Merck Sharp & Dohme LLC2 trials
• Amgen1 trial
• Anthos Therapeutics, Inc.1 trial
• and 5 more

Running trials

• Recruiting

  Study of an Injectable Regimen of GS-3242 with Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment

  2026-526026-40-00· Phase 2/3· Gilead Sciences Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Phase 3 Trial Comparing Whether BEM/RZR is Similar to SOF/VEL in Patients with Hepatitis C Virus Infection

  2025-521096-31-00· Phase 3· Atea Pharmaceuticals Inc.· Source

• Recruiting

  A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

  NCT06935370· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure

  NCT06929806· Phase 3· Pharmacosmos A/S· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

  NCT06481891· Phase 3· Lexicon Pharmaceuticals· Source

• Recruiting

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

  NCT06424288· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

  NCT06312137· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

  NCT06136650· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

  NCT05712200· Phase 3· Anthos Therapeutics, Inc.· Source

• Active, not recruiting

  Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

  NCT03937154· Phase 3· Amgen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure3 recruiting
• Lung cancer2 recruiting
• Atrial fibrillation1 recruiting
• Chronic kidney disease1 recruiting
• HIV1 recruiting
• Prostate cancer1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated

  2024-512505-66-00· Phase 2/3· Gilead Sciences Inc.· Source

• Completed

  EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

  NCT04509674· Phase 3· Boehringer Ingelheim· Source